A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Assessing the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Hormone Receptor-Positive HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer (MORPHEUS-HR+ Breast Cancer). Here, ERBB2 is linked to breast cancer.